|
KMID : 1137020240350010030
|
|
Journal of Gynecologic Oncology
2024 Volume.35 No. 1 p.30 ~ p.30
|
|
|
Recent breakthroughs in the management of locally advanced and recurrent/metastatic cervical cancer
|
|
Eduardo Garcia
Natalie Ayoub
Krishnansu S. Tewari
|
|
|
Abstract
|
|
|
|
Cervical cancer continues to be a global threat affecting individuals in resource poor communities disproportionately. The treatment paradigm for this disease is ever evolving with recent innovations propelling oncologic outcomes to a new frontier offering survival benefits for patients struggling with locally advanced disease and metastatic/recurrent carcinoma. Immunologic checkpoint inhibitors and anti-body drug conjugates represent two novel drug classes that have demonstrable activity in this disease, particularly in the first-line and second-line treatment paradigm for recurrence. The tolerability of these novel medicines and associated durable responses underscore regulatory approval by the U.S. Food and Drug Administrations and their implementation in clinic.
|
|
|
KEYWORD
|
|
|
Cervical Cancer, Chemoradiation, Immune Checkpoint Inhibitor, Antibody Drug Conjugate, Immunotherapy
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|